Related Experiment Videos
Teratogenesis and immunosuppressive treatment
1Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants, and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy. r.danesi@med.unipi.it
Transplantation Proceedings
|April 28, 2004
Summary
Pregnancy after organ transplantation is increasingly common and generally safe for newborns. Careful management of immunosuppressive drugs is key to minimizing risks for both mother and child.
Area of Science:
- Transplantation immunology
- Maternal-fetal medicine
- Pharmacology
Background:
- Organ transplant recipients face potential risks during pregnancy due to immunosuppressive drugs.
- Advancements have led to more frequent uneventful pregnancies in this population.
Purpose of the Study:
- To evaluate the safety and outcomes of pregnancy in organ transplant recipients on immunosuppressive therapy.
- To assess the risks of immunosuppressive drugs on fetal development and graft function.
Main Methods:
- Review of clinical data and published case reports on pregnancies in organ transplant recipients.
- Analysis of the effects of specific immunosuppressive agents (corticosteroids, basiliximab, azathioprine) on pregnancy outcomes.
Main Results:
- No apparent increase in congenital malformations or graft dysfunction observed.
- Pregnancy-related complications like premature birth and low birth weight may be more frequent.
- Specific immunosuppressants like corticosteroids and basiliximab show low fetal malformation rates; azathioprine has a small teratogenic risk.
- Breastfeeding appears safe despite initial recommendations against it due to low drug transfer and infant absorption.
Conclusions:
- Immunosuppressive therapy with selected agents can be continued during pregnancy with careful monitoring.
- A 2-year waiting period post-transplantation is recommended before conception for stable graft function and reduced drug dosage.
- Available data suggest that the benefits of continuing necessary immunosuppression outweigh the potential risks for most transplant recipients during pregnancy.